An investigation on behalf of investors in Alcobra Ltd (NASDAQ:ADHD) shares over potential wrongdoing at Alcobra Ltd was announced and NASDAQ:ADHD stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 01/23/2017 --Alcobra Ltd is under ivnestgiation over potential securities laws violations. The investigation was announced on behalf of investors in shares of Alcobra Ltd (NASDAQ:ADHD) in connection with certain statements made by Alcobra Ltd and certain of its officers and directors.

Investors who purchased shares of Alcobra Ltd (NASDAQ:ADHD) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns also whether certain Alcobra Ltd officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Alcobra Ltd is an Israel-based Biopharmaceutical company that focuses on the development and commercialization of a proprietary drug, MG01CI, to treat ADHD. On January 17, 2017, Alcobra Ltd reported the top-line results from MEASURE, its second Phase 3 clinical trial for the investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. Alcobra Ltd said that in this trial, MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners' Adult ADHD Rating Scales (CAARS). Shares of Alcobra Ltd (NASDAQ:ADHD) declined on January 17, 2017, to as low as $0.83 per share.

On January 20, 2017, NASDAQ:ADHD shares closed at $0.99 per share.

Those who purchased shares of Alcobra Ltd (have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com